The Asia-Pacific bladder cancer therapeutics and diagnostics market is projected to register a CAGR of approximately 5%, during the forecast period (2018-2023).

Increasing Awareness about Bladder Diseases and Available Therapies

Based on the data from International Agency for Research on Cancer, bladder cancer is the 6th most commonly diagnosed cancer of males and the 9th leading cause of cancer deaths worldwide. Historically, bladder cancer has been associated with low patient awareness. Smoking has a high correlation with bladder cancer and this association is mostly unknown to the general public. But, in recent years, the awareness regarding bladder diseases and their management has drastically improved, particularly in developed nations. Also the rise of immunotherapy therapies in cancer treatment has rekindled interest among eligible patients as it is a recently developed treatment modality, and has lower side-effects when compared to radiation therapy and chemotherapy, which are conventional therapeutic options in bladder cancer management. Therefore, the increasing awareness about bladder cancer and related therapies, is fuelling the growth of global bladder cancer therapeutics and diagnostics market. Apart from these, factors, like increasing healthcare expenditure and innovations in novel drug development, is also contributing to the growth of this market.

Asymptomatic Nature of the Disease  

In Asia-Pacific region, the most common type of bladder cancer is transitional cell carcinoma. More than 90% of all cases of bladder cancer are classified as transitional cell carcinomas. Most newly diagnosed transitional cell carcinomas present as superficial tumors. However, the accuracy of diagnostic tests, like urine cytology for identifying bladder cancer is considerably low, particularly in asymptomatic patients with no history of bladder cancer. The symptoms for bladder cancer, like with most other cancers, manifest completely only in advanced stages and early stages have no peculiar symptoms which can assist in patient differentiation. High rate of failure in early detection of bladder cancer is a direct outcome of this limitation. The countries of Asia-Pacific are largely emerging economies and negative outcomes in diagnosis of cancer, presents as an economic challenge for patients and discourages the prospective candidates from undergoing such diagnostic modality. Therefore, the asymptomatic nature of bladder cancer is restricting the growth of Asia-Pacific bladder cancer therapeutics and diagnostics market. Apart from these factors, like increasing number of patent expiries of oncology drugs is limiting the growth of this market. Asia-Pacific region has a large base of generic drug manufacturers and in the event of patent expiry, this region is usually the pioneer in introducing generic versions of the same drug. The lower cost and comparable efficacy of generic drugs usually means greater adoption rates which should ideally contribute to market growth. But, in this case, higher adoption rate is offset by the drastic lowering in prices of generic versions of branded drugs, thereby, hindering market growth.   

Radiation Therapy Leads the Therapeutics Segment

The most advanced modalities of bladder cancer therapeutics include immunotherapy but, the most widely used modality in bladder cancer is radiation therapy. This is due to historical use-prevalence of radiation therapies in various forms of cancers and also because chemotherapy is associated with low specificity and side-effects. Radiation therapy also offers best in class efficacy, in terms of dose frequency and pricing, when compared to other therapeutic modalities in bladder cancer management. Consequently, radiation therapy leads the therapeutics segment in Asia-Pacific bladder cancer therapeutics and diagnostics market.

Key Developments in the Market

• May 2017 – US FDA granted accelerated approval for Pfizer’s immune-oncology drug Bavencio to treat advanced bladder cancer
• December 2017 - TARIS Biomedical LLC, and Bristol-Myers Squibb announced that the companies have entered into a clinical trial collaboration to evaluate the safety, tolerability, and preliminary efficacy of TARIS’ investigational product, TAR-200 (GemRIS™), in combination with Bristol-Myers Squibb’s programmed death-1 (PD-1) immune checkpoint inhibitor, Opdivo (nivolumab) 

The major players include – Novartis International AG, Pfizer Inc., GlaxoSmithKline Plc., Sanofi S.A., Eli Lilly and Co., Astra Zeneca Plc., Bristol Myers Squibb, Hoffmann-La Roche AG, and Celgene Corporation, among others.

Reasons to Purchase this Report

• Current and future Asia-Pacific bladder cancer therapeutics and diagnostics market outlook in the developed and emerging markets
• Analyzing various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness fastest growth during the forecast period
• Identifying the latest developments, market shares, and strategies employed by the major market players
• 3-month analyst support, along with the Market Estimate sheet (in excel)

Customization of the Report

• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs